The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence

På svenska

Author

  • Nadia Stefanova
  • Martin Kollensperger
  • Monika Hainzer
  • Angela Cenci Nilsson
  • Werner Poewe
  • Gregor Karl Wenning

Summary, in English

Levodopa is generally regarded the first choice therapy for parkinsonism associated with multiple system atrophy (MSA-P). However, MSA-P patients often show a poor or unsustained levodopa response which inflicts high dose therapy. This is generally attributed to progressive striatal degeneration with loss of dopamine receptors. Experimental evidence suggests that dopaminergic stimulation may accelerate the striatal disease process in MSA, possibly by pro-oxidative mechanisms. Intact nigrostriatal dopamine release augments striatal lesion size in the unilateral nigral and striatal double lesion rat model of MSA-P. Further, neuronal vulnerability to exogenous oxidative stress is increased in a transgenic MSA mouse model with oligodendroglial alpha-synuclein inclusions. The aim of the present study was to analyze whether high dose levodopa delivery in the transgenic MSA model is associated with neurotoxicity exacerbated by the presence of oligodendroglial alpha-synuclein inclusion pathology. Control and transgenic MSA mice underwent pulsatile treatment with either vehicle, low or high dose levodopa for a period of 1 month. Behavioral and neuropathological indices failed to show evidence for neurotoxic effects of high-dose levodopa in this alpha-synuclein transgenic MSA model. These findings support the idea that high dose levodopa therapy in MSA is not detrimental to the underlying neuropathological process. (C) 2007 Movement Disorder Society.

Publishing year

2007

Language

English

Pages

969-973

Publication/Series

Movement Disorders

Volume

27

Issue

7

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Neurology

Keywords

  • levodopa
  • neurodegeneration
  • glial cytoplasmic inclusions
  • alpha-synuclein
  • multiple system atrophy
  • transgenic mouse

Status

Published

Research group

  • Basal Ganglia Pathophysiology

ISBN/ISSN/Other

  • ISSN: 0885-3185